Advancing analytical innovation and education for integrated continuous manufacturing of therapeutic biomolecules

推进治疗生物分子集成连续制造的分析创新和教育

• 批准号: 67611
• 金额: $ 17.28万
• 依托单位: UNIVERSITY OF CENTRAL LANCASHIRE
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=67611
• 关键词: Advancing; analytical; innovation; education; integrated

The vast majority of vaccines and biological drugs are manufactured in a batch process as a one off and then divided into smaller units of the supplied medicine. Because there can be differences between batches, and to lower production costs and enhance quality, there is much interest from the drug approval agencies and the drug manufacturers to produce drugs in a continuous production line manner. This new approach requires the development of modified processes, new monitoring tools, and new control systems to ensure high performance so that it can be widely adopted. The project allows a university-industry team to evaluate pioneering technology, and, in the exchange of ideas and knowledge, help a university to be better able to educate of the next generation of medicines manufactucting scientists.

绝大多数疫苗和生物药物都是一次性分批生产的，然后分成更小的供应药物单位。由于批次之间可能存在差异，并且为了降低生产成本和提高质量，药品审批机构和药品生产企业对以连续生产线方式生产药品非常感兴趣。这种新方法需要开发改进的过程、新的监测工具和新的控制系统，以确保高性能，从而可以被广泛采用。该项目允许大学-工业团队评估开创性技术，并在思想和知识的交流中帮助大学更好地培养下一代药物制造科学家。